super ace 88

super ace 88 KORE Announces NYSE Acceptance of Plan to Regain Listing Compliance

Core Molding Technologies, Inc. ( NYSEAMERICAN:CMT – Get Free Report ) CEO David L. Duvall sold 4,500 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $16.47, for a total transaction of $74,115.00. Following the completion of the sale, the chief executive officer now directly owns 238,841 shares in the company, valued at approximately $3,933,711.27. The trade was a 1.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link . Core Molding Technologies Price Performance Shares of CMT opened at $16.51 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.98 and a current ratio of 2.41. The stock has a market capitalization of $147.93 million, a PE ratio of 9.33 and a beta of 1.75. Core Molding Technologies, Inc. has a fifty-two week low of $14.64 and a fifty-two week high of $21.00. Core Molding Technologies ( NYSEAMERICAN:CMT – Get Free Report ) last released its quarterly earnings results on Tuesday, November 5th. The industrial products company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.13. The business had revenue of $72.99 million during the quarter, compared to the consensus estimate of $71.57 million. Core Molding Technologies had a return on equity of 10.76% and a net margin of 4.95%. As a group, equities research analysts anticipate that Core Molding Technologies, Inc. will post 1.64 EPS for the current fiscal year. Institutional Investors Weigh In On Core Molding Technologies Core Molding Technologies Company Profile ( Get Free Report ) Core Molding Technologies, Inc, together with its subsidiaries, operates as a molder of thermoplastic and thermoset structural products. The company offers a range of manufacturing processes that include compression molding of sheet molding compound, resin transfer molding, liquid molding of dicyclopentadiene, spray-up and hand-lay-up, direct long-fiber thermoplastics, and structural foam and structural web injection molding. See Also Receive News & Ratings for Core Molding Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Molding Technologies and related companies with MarketBeat.com's FREE daily email newsletter .Blue Jays, Eric Lauer Agree To Minor League Deal

Tyler Technologies CFO sells shares for $1.58 million

NoneNone

LAS VEGAS (AP) — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. “As the pinnacle of motorsports, F1 demands boundary-pushing innovation and excellence. It’s an honor for General Motors and Cadillac to join the world’s premier racing series, and we’re committed to competing with passion and integrity to elevate the sport for race fans around the world,” GM President Mark Reuss said. “This is a global stage for us to demonstrate GM’s engineering expertise and technology leadership at an entirely new level.” The approval ends years of wrangling that launched a U.S. Justice Department investigation into why Colorado-based Liberty Media, the commercial rights holder of F1, would not approve the team initially started by Michael Andretti. Andretti in September stepped aside from leading his namesake organization, so the 11th team will be called Cadillac F1 and be run by new Andretti Global majority owners Dan Towriss and Mark Walter. The team will use Ferrari engines its first two years until GM has a Cadillac engine built for competition in time for the 2028 season. Towriss is the the CEO and president of Group 1001 and entered motorsports via Andretti’s IndyCar team when he signed on financial savings platform Gainbridge as a sponsor. Towriss is now a major part of the motorsports scene with ownership stakes in both Spire Motorsports’ NASCAR team and Wayne Taylor Racing’s sports car team. Walter is the chief executive of financial services firm Guggenheim Partners and the controlling owner of both the World Series champion Los Angeles Dodgers and Premier League club Chelsea. “We’re excited to partner with General Motors in bringing a dynamic presence to Formula 1,” Towriss said. “Together, we’re assembling a world-class team that will embody American innovation and deliver unforgettable moments to race fans around the world.” Mario Andretti, the 1978 F1 world champion, will have an ambassador role with Cadillac F1. But his son, Michael, will have no official position with the organization now that he has scaled back his involvement with Andretti Global. “The Cadillac F1 Team is made up of a strong group of people that have worked tirelessly to build an American works team,” Michael Andretti posted on social media. “I’m very proud of the hard work they have put in and congratulate all involved on this momentous next step. I will be cheering for you!” The approval has been in works for weeks but was held until after last weekend’s Las Vegas Grand Prix to not overshadow the showcase event of the Liberty Media portfolio. Max Verstappen won his fourth consecutive championship in Saturday night’s race, the third and final stop in the United States for the top motorsports series in the world. Grid expansion in F1 is both infrequent and often unsuccessful. Four teams were granted entries in 2010 that should have pushed the grid to 13 teams and 26 cars for the first time since 1995. One team never made it to the grid and the other three had vanished by 2017. There is only one American team on the current F1 grid — owned by California businessman Gene Haas — but it is not particularly competitive and does not field American drivers. Andretti’s dream was to field a truly American team with American drivers. The fight to add this team has been going on for three-plus years and F1 initially denied the application despite approval from F1 sanctioning body FIA . The existing 10 teams, who have no voice in the matter, also largely opposed expansion because of the dilution in prize money and the billions of dollars they’ve already invested in the series. Andretti in 2020 tried and failed to buy the existing Sauber team. From there, he applied for grid expansion and partnered with GM, the top-selling manufacturer in the United States. The inclusion of GM was championed by the FIA and president Mohammed Ben Sulayem, who said Michael Andretti’s application was the only one of seven applicants to meet all required criteria to expand F1’s current grid. “General Motors is a huge global brand and powerhouse in the OEM world and is working with impressive partners,” Ben Sulayem said Monday. “I am fully supportive of the efforts made by the FIA, Formula 1, GM and the team to maintain dialogue and work towards this outcome of an agreement in principle to progress this application.” Despite the FIA’s acceptance of Andretti and General Motors from the start, F1 wasn’t interested in Andretti — but did want GM. At one point, F1 asked GM to find another team to partner with besides Andretti. GM refused and F1 said it would revisit the Andretti application if and when Cadillac had an engine ready to compete. “Formula 1 has maintained a dialogue with General Motors, and its partners at TWG Global, regarding the viability of an entry following the commercial assessment and decision made by Formula 1 in January 2024,” F1 said in a statement. “Over the course of this year, they have achieved operational milestones and made clear their commitment to brand the 11th team GM/Cadillac, and that GM will enter as an engine supplier at a later time. Formula 1 is therefore pleased to move forward with this application process.” Yet another major shift in the debate over grid expansion occurred earlier this month with the announced resignation of Liberty Media CEO Greg Maffei, who was largely believed to be one of the biggest opponents of the Andretti entry. Other news outlets have retreated behind paywalls. At HuffPost, we believe journalism should be free for everyone. Would you help us provide essential information to our readers during this critical time? We can't do it without you. Can't afford to contribute? Support HuffPost by creating a free account and log in while you read. You've supported HuffPost before, and we'll be honest — we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you. Whether you give once or many more times, we appreciate your contribution to keeping our journalism free for all. You've supported HuffPost before, and we'll be honest — we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you. Whether you give just one more time or sign up again to contribute regularly, we appreciate you playing a part in keeping our journalism free for all. Already contributed? Log in to hide these messages. “With Formula 1’s continued growth plans in the US, we have always believed that welcoming an impressive US brand like GM/Cadillac to the grid and GM as a future power unit supplier could bring additional value and interest to the sport,” Maffei said. “We credit the leadership of General Motors and their partners with significant progress in their readiness to enter Formula 1.” ___ AP auto racing: https://apnews.com/hub/auto-racing Related From Our PartnerNon-Cystic Fibrosis Bronchiectasis Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies Involved by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici 12-23-2024 11:12 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 15+ key companies continuously working towards developing 15+ Non-Cystic Fibrosis Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. "Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2024 [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis Market. Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report: * Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years. * Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment * Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years. * In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a biotechnology company dedicated to developing high-purity, pathogen-specific bacteriophage therapeutics for chronic pulmonary diseases and antibiotic-resistant bacterial infections, today announced promising topline results from its Phase 2 "Tailwind" trial. The trial evaluated AP-PA02, a novel inhaled multi-phage therapeutic for treating chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections in patients with non-cystic fibrosis bronchiectasis (NCFB). * In May 2024, Insmed's stock more than doubled following the announcement that its lead pipeline candidate, brensocatib, successfully completed a Phase III trial. The much-anticipated ASPEN trial (NCT04594369) was a global, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. * In July 2023, Zambon, a global pharmaceutical company dedicated to innovating treatments and enhancing the health and well-being of patients, revealed the conclusive findings from the Phase 3 PROMIS-I and PROMIS-II studies. These results were unveiled during the 2023 6th World Bronchiectasis Conference held in New York, NY. Non-Cystic Fibrosis Bronchiectasis Overview Non-cystic fibrosis bronchiectasis is a chronic lung condition characterized by the permanent widening and damage of the airways in the lungs, which leads to persistent coughing, excessive mucus production, and frequent respiratory infections. Unlike cystic fibrosis, it is not caused by a genetic defect in the CFTR gene. Non-cystic fibrosis bronchiectasis can result from various underlying conditions such as chronic infections, immune system disorders, or other lung diseases. Symptoms include chronic cough, shortness of breath, and fatigue. Treatment typically involves antibiotics to manage infections, bronchodilators, and airway clearance techniques to reduce symptoms and improve lung function. Get a Free Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight [ https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include: * NP339: NovaBiotics Ltd * Research Programme:NCFB: Synspira Therapeutics * Research programme: mucolytic agents: Parion Sciences * CHF 6333: Chiesi Farmaceutic * CSL787: CSL Behring * HSK31858: Haisco Pharmaceutical * S-1226: SolAeroMed Inc. * Benralizumab: AstraZeneca * Colistimethate sodium: Zambon SpA * BI 1291583: Boehringer Ingelheim * AP-PA02: Armata Pharmaceuticals * ARINA-1: Renovion Non-Cystic Fibrosis Bronchiectasis Route of Administration Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as * Intravenous * Subcutaneous * Oral * Intramuscular Non-Cystic Fibrosis Bronchiectasis Molecule Type Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as * Monoclonal antibody * Small molecule * Peptide Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment * Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type * Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type * Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration * Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration * Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type * Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type DelveInsight's Non-Cystic Fibrosis Bronchiectasis Report covers around 15+ products under different phases of clinical development like * Late-stage products (Phase III) * Mid-stage products (Phase II) * Early-stage product (Phase I) * Pre-clinical and Discovery stage candidates * Discontinued & Inactive candidates * Route of Administration Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include: Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are - Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others. Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis: The Non-Cystic Fibrosis Bronchiectasis pipeline report provides insights into * The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same. * It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment. * Non-Cystic Fibrosis Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. * Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. * Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers * Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market. Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers * However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth. Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight * Coverage: Global * Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others * Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others * Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies * Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Table of Contents 1. Non-Cystic Fibrosis Bronchiectasis Report Introduction 2. Non-Cystic Fibrosis Bronchiectasis Executive Summary 3. Non-Cystic Fibrosis Bronchiectasis Overview 4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment 5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics 6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III) 7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II) 8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I) 9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products 10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment 11. Non-Cystic Fibrosis Bronchiectasis Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Non-Cystic Fibrosis Bronchiectasis Key Companies 14. Non-Cystic Fibrosis Bronchiectasis Key Products 15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs 16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers 17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion 18. Non-Cystic Fibrosis Bronchiectasis Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=noncystic-fibrosis-bronchiectasis-pipeline-insights-2024-therapies-clinical-trials-and-key-companies-involved-by-delveinsight-insmed-inc-astrazeneca-zambon-csl-behring-chiesi-farmaceutici ] Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.